These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2048 related articles for article (PubMed ID: 26409604)

  • 21. Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China.
    Guan H; Liu G; Xie F; Sheng Y; Shi L
    Clin Ther; 2019 Nov; 41(11):2308-2320.e11. PubMed ID: 31607559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene-guided gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive non-small cell lung cancer: an economic analysis.
    Zhu J; Li T; Wang X; Ye M; Cai J; Xu Y; Wu B
    BMC Cancer; 2013 Jan; 13():39. PubMed ID: 23360224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.
    Dickson R; Bagust A; Boland A; Blundell M; Davis H; Dundar Y; Hockenhull J; Martin Saborido C; Oyee J; Ramani VS
    Pharmacoeconomics; 2011 Dec; 29(12):1051-62. PubMed ID: 21967156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
    Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
    Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
    Bradbury PA; Tu D; Seymour L; Isogai PK; Zhu L; Ng R; Mittmann N; Tsao MS; Evans WK; Shepherd FA; Leighl NB;
    J Natl Cancer Inst; 2010 Mar; 102(5):298-306. PubMed ID: 20160168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Feasibility Study of Sequentially Alternating EGFR-TKIs and Chemotherapy for Patients with Non-small Cell Lung Cancer.
    Takemura Y; Chihara Y; Morimoto Y; Tanimura K; Imabayashi T; Seko Y; Kaneko Y; Date K; Ueda M; Arimoto T; Iwasaki Y; Takayama K
    Anticancer Res; 2018 Apr; 38(4):2385-2390. PubMed ID: 29599365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective.
    Thongprasert S; Tinmanee S; Permsuwan U
    Asia Pac J Clin Oncol; 2012 Mar; 8(1):53-61. PubMed ID: 22369444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China.
    Cai H; Zhang L; Li N; Chen S; Zheng B; Yang J; Weng L; Liu MB
    Clin Ther; 2019 Feb; 41(2):280-290. PubMed ID: 30639208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.
    Schuler M; Wu YL; Hirsh V; O'Byrne K; Yamamoto N; Mok T; Popat S; Sequist LV; Massey D; Zazulina V; Yang JC
    J Thorac Oncol; 2016 Mar; 11(3):380-90. PubMed ID: 26823294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer.
    Wang H; Zeng C; Li X; Wang Y; Li X; Ge W
    Future Oncol; 2019 Jan; 15(2):181-191. PubMed ID: 30320506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
    Aguiar PN; Haaland B; Park W; San Tan P; Del Giglio A; de Lima Lopes G
    JAMA Oncol; 2018 Aug; 4(8):1080-1084. PubMed ID: 29852038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.
    Nishiyama A; Katakami N; Yoshioka H; Iwasaku M; Korogi Y; Hata A; Takeshita J; Otsuka K; Nishino K; Uchida J; Okuyama T; Namba Y; Mori M; Fujita S; Morita S
    Lung Cancer; 2015 Sep; 89(3):301-5. PubMed ID: 26141215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.
    Lee VH; Leung DK; Choy TS; Lam KO; Lam PM; Leung TW; Kwong DL
    BMC Cancer; 2016 Feb; 16():147. PubMed ID: 26911310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
    Takeda M; Okamoto I; Nakagawa K
    Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective, multicenter phase II trial of low-dose erlotinib as maintenance treatment after platinum doublet chemotherapy for advanced non-small cell lung cancer harboring EGFR mutation.
    Hirano S; Naka G; Takeda Y; Iikura M; Hayama N; Yanagisawa A; Amano H; Nakamura M; Nakamura S; Tabeta H; Sugiyama H
    Chin Clin Oncol; 2016 Dec; 5(6):77. PubMed ID: 28061541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment.
    Chin TM; Quinlan MP; Singh A; Sequist LV; Lynch TJ; Haber DA; Sharma SV; Settleman J
    Clin Cancer Res; 2008 Nov; 14(21):6867-76. PubMed ID: 18980981
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.
    Halmos B; Pennell NA; Fu P; Saad S; Gadgeel S; Otterson GA; Mekhail T; Snell M; Kuebler JP; Sharma N; Dowlati A
    Oncologist; 2015 Nov; 20(11):1298-303. PubMed ID: 26306902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.
    Burotto M; Manasanch EE; Wilkerson J; Fojo T
    Oncologist; 2015 Apr; 20(4):400-10. PubMed ID: 25795635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia.
    Khoo T; Gao L
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):415-423. PubMed ID: 33151783
    [No Abstract]   [Full Text] [Related]  

  • 40. Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation.
    Yoshimura N; Kudoh S; Mitsuoka S; Yoshimoto N; Oka T; Nakai T; Suzumira T; Matusura K; Tochino Y; Asai K; Kimura T; Kawaguchi T; Hirata K
    Lung Cancer; 2015 Oct; 90(1):65-70. PubMed ID: 26238424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 103.